Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Verrica Pharmaceuticals' Lead Product, Ycanth, Has Received New Chemical Entity Status And A Listing In The Orange Book From The FDA, Providing A Minimum of Five Years Of Regulatory Exclusivity

Author: Benzinga Newsdesk | March 26, 2024 07:33am

NCE status provides a minimum of five years of regulatory exclusivity
The Company's U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension

Posted In: VRCA